125 related articles for article (PubMed ID: 14751188)
1. Oral altretamine used as salvage therapy in recurrent ovarian cancer.
Chan JK; Loizzi V; Manetta A; Berman ML
Gynecol Oncol; 2004 Jan; 92(1):368-71. PubMed ID: 14751188
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
Alberts DS; Jiang C; Liu PY; Wilczynski S; Markman M; Rothenberg ML
Int J Gynecol Cancer; 2004; 14(2):224-8. PubMed ID: 15086720
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Rustin GJ; Nelstrop AE; Crawford M; Ledermann J; Lambert HE; Coleman R; Johnson J; Evans H; Brown S; Oster W
J Clin Oncol; 1997 Jan; 15(1):172-6. PubMed ID: 8996139
[TBL] [Abstract][Full Text] [Related]
4. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
5. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
6. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Keldsen N; Havsteen H; Vergote I; Bertelsen K; Jakobsen A
Gynecol Oncol; 2003 Feb; 88(2):118-22. PubMed ID: 12586589
[TBL] [Abstract][Full Text] [Related]
7. Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR; Faulds D
Drugs; 1995 Jun; 49(6):932-53. PubMed ID: 7641606
[TBL] [Abstract][Full Text] [Related]
8. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
9. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
Malik IA
Jpn J Clin Oncol; 2001 Feb; 31(2):69-73. PubMed ID: 11302345
[TBL] [Abstract][Full Text] [Related]
10. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Gershanovich ML; Livshits ME; Antipenkova VI
Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
[TBL] [Abstract][Full Text] [Related]
11. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer.
Davis-Perry S; Hernandez E; Houck KL; Shank R
Am J Clin Oncol; 2003 Aug; 26(4):429-33. PubMed ID: 12902900
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Rothenberg ML; Liu PY; Wilczynski S; Hannigan EV; Weiner SA; Weiss GR; Hunter VJ; Chapman JA; Tiersten A; Kohler PC; Alberts DS
Gynecol Oncol; 2001 Aug; 82(2):317-22. PubMed ID: 11531286
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy for recurrent ovarian cancer].
Nishimura H; Imamura K; Chang C
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
15. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
16. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.
Ferrandina G; Corrado G; Mascilini F; Malaguti P; Samaritani R; Distefano M; Masciullo V; Di Legge A; Savarese A; Scambia G
BMC Cancer; 2014 Dec; 14():947. PubMed ID: 25495785
[TBL] [Abstract][Full Text] [Related]
17. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
18. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
20. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Moore DH; Fowler WC; Jones CP; Crumpler LS
Am J Obstet Gynecol; 1991 Sep; 165(3):573-6. PubMed ID: 1909840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]